Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,837
  • Shares Outstanding, K 2,266
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,850 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.50
  • Number of Estimates 1
  • High Estimate -1.50
  • Low Estimate -1.50
  • Prior Year -18.50
  • Growth Rate Est. (year over year) +91.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.74 +38.08%
on 12/16/25
8.88 -57.43%
on 12/17/25
-3.19 (-45.73%)
since 11/19/25
3-Month
2.74 +38.08%
on 12/16/25
14.24 -73.46%
on 10/08/25
-1.06 (-21.82%)
since 09/19/25
52-Week
2.74 +38.08%
on 12/16/25
27.00 -86.00%
on 01/06/25
-19.79 (-83.96%)
since 12/19/24

Most Recent Stories

More News
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct...

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative...

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer...

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small Stocks,...

PCSA : 3.78 (-3.08%)
BFRG : 1.1300 (+8.65%)
Processa Pharmaceuticals Provides Portfolio and Business Update

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

PCSA : 3.78 (-3.08%)
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

PCSA : 3.78 (-3.08%)

Business Summary

Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who have unmet medical need. Processa Pharmaceuticals Inc., formerly known as Heatwurx Inc., is based in HANOVER, United States.

See More

Key Turning Points

3rd Resistance Point 5.94
2nd Resistance Point 5.42
1st Resistance Point 4.66
Last Price 3.78
1st Support Level 3.38
2nd Support Level 2.86
3rd Support Level 2.10

See More

52-Week High 27.00
Fibonacci 61.8% 17.73
Fibonacci 50% 14.87
Fibonacci 38.2% 12.01
Last Price 3.78
52-Week Low 2.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar